Anti-SARS-CoV-2 Rapid Test

Anti-SARS-CoV-2 Rapid Test is a rapid, one-step lateral flow assay intended for the qualitative detection and differentiation of IgM (early marker) and IgG (late marker) antibodies against the SARS-CoV-2 virus in plasma or serum in patients suspected of a COVID-19 infection. The immunoassay Anti-SARS-CoV-2 Rapid Test is based on a colloidal gold method for the rapid, qualitative determination of Anti-SARS-CoV-2 (IgG/IgM antibodies of Severe Acute Respiratory Syndrome Coronavirus 2) in human serum, plasma or whole blood. This assay is based upon one-step capture method. It contains a membrane, which is pre-coated with two mouse anti-human monoclonal antibodies (anti-IgG and anti-IgM) on two separated test lines.
FDA EUA Approved
Rapid Results – 15 minutes
Clear, easy-to-interpret results
Built-in controls
Room temperature storage
Sample type: human serum, plasma or whole blood

Sensitivity at >/= 15 days after onset of symptoms (FDA Data)

IgM – 95.7% / IgG – 99.0%

Specificity (FDA Data)

IgM – 99% / IgG – 99%

Coming Soon